Surveyor Capital is an investment firm that focuses on increasing access and opportunity to companies and entrepreneurs.
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams operate market neutral strategies and aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 6, 2022
Entact Bio
|
Series A | $81M | Biopharma | — |
Dec 5, 2022
Karyopharm Therapeutics
|
Post-IPO Equity | $165M | Health Care | — |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
Oct 7, 2021
Science 37
|
Post-IPO Equity | $200M | Biotechnology | — |
Oct 7, 2021
Neumora Therapeutics
|
Series A | $400M | Biotechnology | — |